123. Cansas CW, Conn DR, Cjaza Al et al. Frequency anod significance of antibodies to HCV in polyarteritis nodosa. J RheumatoI 1993; 20: 304-309
124. Navas S, Bosch O, Castilla I, et al. Porphyria cutanea tarda and hepatitis C and B viruses infection. A retrospective study. Hepatology 1995;21 :279-282
125. Maurico LM, Bisceglie A, Usala Si, et al. Development of tyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 1992;102:2155-2160
126. Dupin N, Chosidov O, Frances C, et al. Licen planus after interferon alpha therapy for hepatitis C Eur J DermatoI1994;4:435
127. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis in Sjögren’s syndrome associated with HCV liver disease. Lancet 1992;339:321-323
128. Mason A, Lau J, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-333
129. Ergün Y, Işıksal F, Akkız H ve ark. HCV (+) kronik karaciğer hastalarında diyabetes mellitus sıklığı. IV. Ulusal Hepatoloji Kongresi, İstanbul. Özet kitabı, S: 132
130. Kaymakoglu S, Durakoglu Z, Demir K, et al. What are the responsible factors of the development of diabetes mellitus in chronic liver disease? J Hepatol 2000;32 (supp):126
131. Uzunalimoğlu Ö, Bozkaya H, Çetinkaya H, ve ark. Behçet hastalığı ve hepatit C virusu arasında bir ilişki var mı? Turkish J Gastroenterology 1998;9:10-13.
132. NIH Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997;26 (suppl.1):2-10
133. Consensus Statement “EASL International Consensus Conference on Hepatitis C”. J HepatoI 1999;30:956-61
65



73. SAYFAYA BENZER SAYFALAR

tabs_sener_yagiz_191898 - Sayfa
...


73. SAYFA ICERIGI

123. Cansas CW, Conn DR, Cjaza Al et al. Frequency anod significance of antibodies to HCV in polyarteritis nodosa. J RheumatoI 1993; 20: 304-309
124. Navas S, Bosch O, Castilla I, et al. Porphyria cutanea tarda and hepatitis C and B viruses infection. A retrospective study. Hepatology 1995;21 :279-282
125. Maurico LM, Bisceglie A, Usala Si, et al. Development of tyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 1992;102:2155-2160
126. Dupin N, Chosidov O, Frances C, et al. Licen planus after interferon alpha therapy for hepatitis C Eur J DermatoI1994;4:435
127. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis in Sjögren’s syndrome associated with HCV liver disease. Lancet 1992;339:321-323
128. Mason A, Lau J, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-333
129. Ergün Y, Işıksal F, Akkız H ve ark. HCV (+) kronik karaciğer hastalarında diyabetes mellitus sıklığı. IV. Ulusal Hepatoloji Kongresi, İstanbul. Özet kitabı, S: 132
130. Kaymakoglu S, Durakoglu Z, Demir K, et al. What are the responsible factors of the development of diabetes mellitus in chronic liver disease? J Hepatol 2000;32 (supp):126
131. Uzunalimoğlu Ö, Bozkaya H, Çetinkaya H, ve ark. Behçet hastalığı ve hepatit C virusu arasında bir ilişki var mı? Turkish J Gastroenterology 1998;9:10-13.
132. NIH Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997;26 (suppl.1):2-10
133. Consensus Statement “EASL International Consensus Conference on Hepatitis C”. J HepatoI 1999;30:956-61
65

İlgili Kaynaklar







single.php